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Department of Surgery, Section of Urology, The Aga Khan University, Karachi.
Abstract
Objective: To evaluate the role of Estrogens (Honvan) in the secondary hormonal manipulation of patients with
hormone refractory prostate cancer (HRCP).
Methods: Twelve patients diagnosed as hormone refractory prostate cancer received intravenous estrogens for
six days (Fosfestrol, a synthetic phosphorylated estrogen derivative), followed by a maintenance oral dose of 120
mg thrice daily as second line hormonal treatment. During the treatment they were given deep venous thrombo-
sis prophylaxis. Their stage at initial presentation, primary treatment, mode of androgen ablation,  prostate spe-
cific antigen (PSA) level, duration of remission prior of HRPC status, PSA doubling time before and after estro-
gen treatment were recorded. The morbidity and mortality of the treatment was also recorded.  A drop in PSA of
> 50% was classified as major responder. The drop of < 50% was defined as minor responders. Treatment fail-
ure was defined as a rise in PSA > the level prior to the start of treatment.
Results:  The mean age at diagnosis of prostate cancer was 66.6 + 5.4 years (range 57-73). At the time of ini-
tial diagnosis only 3 patients (25%) had localized disease and 9 (75%) had metastatic prostate cancer. Six
patients each opted for surgical or medical castration (LHRH analogs) as the mode of androgen ablation. The
mean initial PSA at diagnosis was 340 + 728.1 ng/ml (range 4.1-2375, Median 94). After development of HRPC,
six patients (50%) had major response, four (33%) had minor response to estrogen administration. Two patients
(17%) did not respond to estrogens.  The mean PSA before receiving Fosfestrol was 60.5 + 82 ng/ml (range
0.013-246). The PSA (nadir) after treatment was 24.3 + 33.2 ng/ml (range 0.9-81.3). One patient developed
gynaecomastia and one had congestive cardiac failure.  Two patients died of non cancer related deaths and one
patient died of cancer related death.  
Conclusion:  Synthetic estrogens are well tolerated, in-expensive agents and could be considered for palliative
use against hormone resistant prostate cancer (JPMA 54:445;2004).
Introduction
Hormone refractory prostate cancer is a leading
cause of cancer related death in males in the western world.
In 2003 alone, it was estimated that 28,900 deaths would
occur due to carcinoma prostate in the United States.1 Due
to lack of mass screening programs, the incidence of
prostate cancer is perceived to be much less in the develop-
ing world and hence, only a minority of patients are found
to have localized disease.2,3 As majority of patients in the
less developed countries seek medical attention with symp-
toms and complication of advanced prostate cancer, early
development of hormone refractory status is observed and a
short course towards the terminal event in metastatic hor-
mone refractory cancers is seen.4
The role of hormonal manipulation in prostate can-
cer was first established in the mid twentieth century when
Huggins and Hodges demonstrated that castration and
administration of estrogens resulted in regression of disease,
which was reversed by administration of testosterone.5
However this regression is not durable. Majority of patients
initially treated with androgen blockade would exhibit
regression of disease however the median duration of
response is brief.6 At this point in the natural history a pro-
portion of patients may still be sensitive to secondary hor-
monal manipulation and chemotherapy.7,8 These interven-
tions result in improvement in survival and quality of life
for some patients.9 A gold standard in treatment of HRCP is
yet to be set, various protocols have been developed in the
past, including the use of different derivatives of estrogens
e.g fosfestrol (diethylstilbestrol disphosphate, Honvan, Asta
pharmaceutical TM) for treating HRPC. Direct cytotoxic
effect of this therapy was proved in trials with continuous
infusion of high dose of fosfestrol.10,11 This effect has result-
ed in more than 50% regression of biochemical disease with
a majority of patients experiencing marked subjective
improvement in symptoms.12 
As a significant proportion of  patients present with
advanced cancer and develop hormone refractory prostate
cancer, there is a need to define a protocol which would lead
to regression of disease, increase survival and reduce or
delay suffering. 
The role of Fosfestrol (Honvan) in the control of dis-
ease in hormone refractory prostate cancer was reviewed.
Patients and Methods
All the patients diagnosed as hormone refractory
prostate cancer and treated with Fosfestrol (Honvan) from
January 1991 to December 2001 were included. Hormone
refractory prostate cancer (HRPC) was defined as a state
when despite androgen blockade by either surgical or med-
ical castration there is progression of disease manifested by
either a rise in prostate specific antigen (PSA) or develop-
ment of new metastasis on imaging studies. 
Twelve patients received 500mg of Injection
Fosfestrol (Honvan) intravenous diluted in 100cc of normal
saline and infused over 2-3 hours on the first day followed
by 1000mg for the five days. There after they received a
maintenance oral dose of 120 mg thrice daily. During hospi-
talization they were given deep vein thrombosis (DVT) pro-
phylaxis with 5000 IU of heparin subcutaneous twice daily
and on discharge they were prescribed, 1 mg of warfarin and
300mg of aspirin once daily. During the therapy they were
regularly monitored for development of DVT, cerebro-vas-
cular accident (CVA), congestive cardiac failure, gynaeco-
mastia and other complications. 
The stage at presentation, primary mode of treat-
ment, mode of androgen ablation, nadir PSA, period of
remission, PSA before fosfestrol treatment, PSA doubling
time before and after the treatment, duration of response,
and overall survival were recorded. A drop in PSA of >50%
was classified as major response. The drop of <50% was
defined as minor responders. Non-responder was defined as
a rise in PSA > the level prior to the start of treatment after
excluding other causes of raised PSA. The disease progression
on imaging study was also recorded as treatment failure. The
duration of response was defined as the period from the start
of treatment to progression of disease on imaging studies or
a PSA level, double the pre-treatment level. The overall sur-
vival was recorded. The morbidities and mortalities related
to treatment were also recorded 
Results
During the 10 year period, 12 patients with HRPC
were treated with estrogens (fosfestrol) according to the
defined protocol. The mean age at presentation was 66.6 +
5.4 years (range 57-73). Seven patients (58%) reported
lower urinary ract symptoms, two patients (17%) each pre-
sented with urinary retention and pathological fracture and
one patient (8%) had bowel obstruction. At the time of ini-
tial diagnosis, 3 patients (25%) had localized disease and
underwent definitive external beam radiation therapy and
nine patients (75%) had metastatic disease (stage D-2). Six
patients (50%) underwent Channel TURP. Six patients each
opted for orchidectomy or medical castration (LHRH
analogs). Two patients received palliative radiation to
metastatic lesions. Two patients also received fosfestrol ini-
tially along with other forms of treatment because of high
volume of biochemical and bone disease. One patient had
well differentiated tumor, six had moderately differentiated
tumor and five had poorly differentiated tumor. The mean
initial PSA was 340 + 728.1ng/ml (range 4.1-2375, Median
94). Three patients who presented in acute retention of urine
did not have a PSA before androgen ablation. The overall
mean period of remission was 25.3 + 24 months, however
mean period of remission for advanced disease was 16+18
months.  Six (50%) patients had major response and 4
(33%) had minor response. Two (17%) patients had no
response. The mean PSA before receiving Fosfestrol was
60.5 + 82 ng/ml (range 0.013-246). The PSA after treatment
was 24.3 + 33.2 ng/ml (range 0.9-81.3). Although there was
a decline in the PSA it was not statistically significant (p-
value 0.24). One patient with very high PSA of 2375 was
excluded. The PSA doubling time before the treatment was
2.7+1.7 months and increased to 3.9+2.4 months after the
treatment. Although a difference was observed it was also
not statistically significant. The mean duration of response
was 12.7 + 14.3 months (range 1-38 months). The mean fol-
low up was 13.6 + 12 months (range 1-38 months). Two
patients died of non cancer related causes. One patient had
aggressive disease; he did not respond to fosfestrol and died
of cancer related causes. One patient died of cancer, nine-
teen months after receiving Fosfestrol. There was morbidity
each of gynaecomastia and congestive cardiac failure. 
Discussion
The transformation of prostate cancer from an early
hormone sensitive status to progressive, metastatic hormone
refractory cancer has been the focus of prostate cancer
research in the last decade. The molecular basis for this phe-
nomenon is not well elucidated.  No single agent or combi-
nation can yet claim to fulfill the long-term goal of achiev-
ing cure. The current goals are more modest i.e. to identify
agents that would increase survival, cause regression of dis-
ease and most important of all improve the quality of life. In
our part of the world where the disease presents at an
advanced stage the need to identify a protocol that is also
cost effective is crucial. We attempted to achieve this lesser
goal with the use of Fosfestrol (C18 H18 Na4 CO8 P2). It is a
synthetic non-steroidal phosphorylated estrogen and
requires dephosphorylation to diethylstilbestrol before its
activation. It is readily absorbed orally. The intra venous and
orally administered drug is metabolized in the liver; a por-
tion is excreted in the bile but is reabsorbed through the
entero-hepatic circulation and the conjugates are
excreted in the urine. In the past Droz et al have demonstrat-
ed that this form of estrogen can be safely used to circum-
vent the hormone resistance and produce tumoricidal
effect.10 He recommended a dose of 4gm/day over 3.5 hours
and reported side effects mainly as nausea, vomiting and
fluid retention. As majority of the men suffering from
HRPC also have concurrent medical problems. The goal of
palliation is to produce disease regression with minimal side
effects. To achieve this objective we attempted to reproduce
the tumoricidal effects using lesser dosages. During the six-
day infusion minimal nausea was reported and all the
patients were able to tolerate three full meals per day.
During the maintenance period none of the patients report-
ed nausea. No patient developed any significant cardiovas-
cular or thrombo-embolic side effect. This demonstrated the
excellent tolerability of lesser doses (1 gm/day). 
An important consideration in the management of
cancers in the developing world is the cost of treatment.
Most chemotherapeutic agents are expensive. The cost of
this drug at our institute was Rs 1190 (USD$ 20) for the
intravenous use and Rs. 45/day (USD$ 0.70) for mainte-
nance therapy which is one of the least expensive forms of
treatment currently available.
Kelly et al demonstrated that a >50% decline in the
PSA level is predictive of improved survival.13 Six out of
twelve of our patients demonstrated a >50% decline and 4
patients showed a <50% decline in the PSA. This 83%
response is far more than response rate of 29% reported
with Mitoxantrone and Prednisone.9 Even more toxic agents
like Doxetaxel and Estramustine have reported a response
rate of 54%.8 The mean duration of response 12.7 + 14.3
months is comparable with the response duration of 10.75
months with Mitoxantrone and Prednisone combination.9
In conclusion synthetic estrogens are well tolerat-
ed and relatively in-expensive agents. The described proto-
col of administration of fosfestrol can be considered for pal-
liative use against hormone resistant prostate cancer.
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